Đang chuẩn bị liên kết để tải về tài liệu:
Báo cáo y học: "Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học General Psychiatry cung cấp cho các bạn kiến thức về ngành y đề tài:Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase. | Available online http arthritis-research.eom content 8 1 R12 Research article Control of hyperuricemia in subjects with refractory gout and induction of antibody against poly ethylene glycol PEG in a phase I trial of subcutaneous PEGylated urate oxidase Nancy J Ganson1 Susan J Kelly1 Edna Scarlett1 John S Sundy1 and Michael S Hershfield1 2 Open Access Division of Rheumatology Box 3049 Duke University Medical Center Durham NC 27710 USA 2Department of Biochemistry Box 3049 Duke University Medical Center Durham NC 27710 USA Corresponding author Michael S Hershfield msh@biochem.duke.edu Received 28 Jul 2005 Revisions requested 21 Sep 2005 Revisions received 10 Oct 2005 Accepted 3 Nov 2005 Published 2 Dec 2005 Arthritis Research Therapy 2006 8 R12 doi 10.1186 ar1861 This article is online at http arthritis-research.com content 8 1 R1 2 2005 Ganson et al. licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License http creativecommons.org licenses by 2.0 which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract PEG-modified recombinant mammalian urate oxidase PEGuricase is being developed as a treatment for patients with chronic gout who are intolerant of or refractory to available therapy for controlling hyperuricemia. In an open-label phase I trial single subcutaneous injections of PEG-uricase 4 to 24 mg were administered to 13 such subjects 11 had tophaceous gout whose plasma uric acid concentration pUAc was 11.3 2.1 mg dl mean SD . By day seven after injection of PEGuricase pUAc had declined by an average of 7.9 mg dl and had normalized in 11 subjects whose mean pUAc decreased to 2.8 2.2 mg dl. At doses of 8 1 2 and 24 mg the mean pUAc at 21 days after injection remained no more than 6 mg dl. In eight subjects plasma uricase activity was still measurable at 21 days after injection half-life 10.5 to 19.9 days . In the other .